266 related articles for article (PubMed ID: 1377002)
1. TP53 tumor suppressor gene: a model for investigating human mutagenesis.
Caron de Fromentel C; Soussi T
Genes Chromosomes Cancer; 1992 Jan; 4(1):1-15. PubMed ID: 1377002
[TBL] [Abstract][Full Text] [Related]
2. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM; Pearson JV; Hayward NK
Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
[TBL] [Abstract][Full Text] [Related]
3. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice.
Hegi ME; Söderkvist P; Foley JF; Schoonhoven R; Swenberg JA; Kari F; Maronpot R; Anderson MW; Wiseman RW
Carcinogenesis; 1993 May; 14(5):803-10. PubMed ID: 8504472
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations in human lung tumors.
Miller CW; Simon K; Aslo A; Kok K; Yokota J; Buys CH; Terada M; Koeffler HP
Cancer Res; 1992 Apr; 52(7):1695-8. PubMed ID: 1312896
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.
Lothe RA; Fossli T; Danielsen HE; Stenwig AE; Nesland JM; Gallie B; Børresen AL
J Natl Cancer Inst; 1992 Jul; 84(14):1100-8. PubMed ID: 1619684
[TBL] [Abstract][Full Text] [Related]
6. Mutation in the TP53 gene in colorectal carcinoma detected by polymerase chain reaction.
Han ES; Moyer MP; Naylor S; Sakaguchi AY
Genes Chromosomes Cancer; 1991 Jul; 3(4):313-7. PubMed ID: 1958596
[TBL] [Abstract][Full Text] [Related]
7. Distinct Rayleigh scattering from hot spot mutant p53 proteins reveals cancer cells.
Jun HJ; Nguyen AH; Kim YH; Park KH; Kim D; Kim KK; Sim SJ
Small; 2014 Jul; 10(14):2954-62. PubMed ID: 24700814
[TBL] [Abstract][Full Text] [Related]
8. Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer.
Shipman R; Schraml P; Colombi M; Raefle G; Dalquen P; Ludwig C
Eur J Cancer; 1996 Feb; 32A(2):335-41. PubMed ID: 8664051
[TBL] [Abstract][Full Text] [Related]
9. Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract.
Law JC; Whiteside TL; Gollin SM; Weissfeld J; El-Ashmawy L; Srivastava S; Landreneau RJ; Johnson JT; Ferrell RE
Clin Cancer Res; 1995 Jul; 1(7):763-8. PubMed ID: 9816043
[TBL] [Abstract][Full Text] [Related]
10. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
11. TP53 tumor-suppressor gene and human carcinogenesis.
Basset-Séguin N; Molès JP; Mils V; Dereure O; Guilhou JJ
Exp Dermatol; 1993 Jun; 2(3):99-105. PubMed ID: 8162331
[TBL] [Abstract][Full Text] [Related]
12. Mutations of p53 gene in gastric carcinoma in Taiwan.
Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
[TBL] [Abstract][Full Text] [Related]
13. TP53 tumor suppressor gene and skin carcinogenesis.
Basset-Séguin N; Molès JP; Mils V; Dereure O; Guilhou JJ
J Invest Dermatol; 1994 Nov; 103(5 Suppl):102S-106S. PubMed ID: 7963669
[TBL] [Abstract][Full Text] [Related]
14. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
15. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
16. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas.
Kannan K; Krishnamurthy J; Feng J; Nakajima T; Tsuchida N; Shanmugam G
Int J Oncol; 2000 Nov; 17(5):1031-5. PubMed ID: 11029509
[TBL] [Abstract][Full Text] [Related]
17. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
[TBL] [Abstract][Full Text] [Related]
18. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
19. Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types.
Gao WM; Mady HH; Yu GY; Siegfried JM; Luketich JD; Melhem MF; Keohavong P
Lung Cancer; 2003 May; 40(2):141-50. PubMed ID: 12711114
[TBL] [Abstract][Full Text] [Related]
20. p53 mutational spectrum of esophageal carcinomas from five different geographical locales in China.
Lung ML; Chan WC; Zong YS; Tang CM; Fok CL; Wong KT; Chan LK; Lau KW
Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):277-84. PubMed ID: 8722219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
